Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Durable responses in metastatic cancers have been achieved with a variety of immunotherapies such as interleukin-2, adoptive cell transfer of tumor-infiltrating lymphocytes, antibodies that block cytotoxic T-lymphocyte–associated antigen 4 (CTLA4), and antibodies that block programmed death 1 (PD-…

from Cancer via ola Kala on Inoreader http://ift.tt/29QKJxd
via IFTTT